Skye Bioscience Business Summary

Skye Bioscience, Inc. (SKYE) is a clinical-stage biopharmaceutical firm specializing in the modulation of the endocannabinoid system to address metabolic health, with a primary focus on obesity and chronic kidney disease. The company follows a pre-revenue business model, deriving its valuation from the clinical progression and potential future licensing or commercialization of its lead candidate, nimacimab—a peripherally restricted negative allosteric modulating antibody targeting the CB1 receptor. Skye’s primary business segment is Metabolic Health, where it aims to provide a differentiated therapeutic profile compared to standard-of-care incretins by enhancing weight loss quality and metabolic homeostasis without central nervous system-mediated side effects. Within the competitive landscape, Skye operates alongside major incumbents such as Novo Nordisk and Eli Lilly, as well as clinical-stage peers like Structure Therapeutics and Terns Pharmaceuticals. Skye distinguishes itself by positioning nimacimab as a potential first-in-class peripheral CB1 inhibitor that can serve as both a monotherapy and a synergistic adjunct to existing GLP-1 receptor agonists. The executive leadership is spearheaded by CEO and Chair Punit Dhillon, who recently consolidated oversight by assuming the role of Principal Accounting Officer in February 2026 following the departure of the former CFO. Dhillon’s background includes significant experience in biotech capital markets and corporate strategy, notably as the former CEO of OncoSec Medical. The core management team includes Chief Medical Officer Dr. Puneet S. Arora, Chief Scientific Officer Chris Twitty, and Chief Operating Officer Tu Diep, all of whom possess extensive experience in translational medicine and metabolic drug development. Governance is further strengthened by Board Chairman Paul Grayson, a seasoned biotech executive with a track record at Fate Therapeutics and BirdRock Bio. Skye maintains a robust institutional shareholder base featuring 5AM Ventures, Versant Ventures, and Perceptive Advisors. The Board of Directors includes influential industry veterans such as Andrew Schwab and Dr. Annalisa Jenkins, ensuring a high level of strategic oversight as the company advances its Phase 2 clinical programs.